How early and aggressive lowering of apoB could change the course of ASCVD

Well SupportedIndividuals with a high burden of cardiovascular disease and lifetime exposure to ApoB should aim for ApoB levels of 30 mg/dL, even if it requires multiple medications.

Well SupportedPeter Attia advocates for earlier and more aggressive reduction of ApoB levels to prevent atherosclerotic cardiovascular disease.

Partially SupportedThe time required to see benefits from lipid-lowering therapy suggests that intervention should not be delayed until a problem like a positive calcium score arises.

How early and aggressive lowering of apoB could change the course of ASCVD | The Peter Attia Drive